SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, announced that it submitted its response to a request for additional information from the U.S. Food and Drug Administration (FDA) on Oct. 5, 2026, regarding its 510(k) submission for the SSi Mantra surgical robotic system. The response includes final data from an expanded human clinical and human factors validation study, as well as a bridging study completed in August 2026 at Hospital Internacional de Colombia, a member of the Mayo Clinic Care Network. The submission covers the initial indication of cholecystectomy, or gallbladder removal. The company anticipates that the FDA will complete its review of the response and 510(k) submission in the first quarter of 2027, advancing its efforts to introduce the SSi Mantra system to the U.S. market. For full details, see the press release at https://ibn.fm/A6dJ8.
The SSi Mantra is a modular, multi-arm surgical robotic system featuring 3 to 5 robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, and a touch panel for patient information. It also offers a virtual real-time image of the robotic patient side arm carts and the ability to superimpose 3D models of diagnostic imaging. An optional tele-surgeon console, the SSi MantrAsana, provides portability and telesurgery capability. The system utilizes over 40 types of robotic endo-surgical instruments, including 5mm instruments for pediatric and ENT surgeries, and has been clinically validated in India in more than 190 different surgical procedures.
This FDA submission matters because it signals progress toward bringing a potentially more affordable surgical robotic option to the U.S. market, whereIntuitive Surgical's da Vinci system has long dominated. SS Innovations aims to make robotic surgery accessible to a larger global population, and U.S. clearance could intensify competition, potentially lowering costs and expanding access to minimally invasive surgery. The company's focus on cardiac surgery and pediatric applications further differentiates its platform. If cleared, the SSi Mantra could offer hospitals an alternative that may reduce capital and per-procedure expenses, impacting how healthcare facilities adopt robotic technology.
For investors and industry watchers, the FDA's decision in early 2027 will be a key catalyst. SS Innovations is headquartered in India but operates as a U.S. company, and its progress is closely followed. The latest updates are available in the company's newsroom at https://ibn.fm/SSII. More information about the company can be found at ssinnovations.com and LinkedIn.
This news is distributed via TechMediaWire, part of the Dynamic Brand Portfolio at IBN, which provides corporate communications solutions to public and private companies. For disclaimers, see https://www.TechMediaWire.com/Disclaimer.
